ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0713

Differentiating Primary Anti-Neutrophil Cytoplasmic Antibody (ANCA) Associated Vasculitis from Secondary Forms

Adil Vural1, Chao Zhang2, Yaseen Kinanah1, Cassandra Calabrese3 and Adam Brown4, 1Cleveland Clinic, Cleveland, OH, 2Cleveland Clinic, Cleveland Heights, OH, 3Cleveland Clinic Foundation, Cleveland Heights, OH, 4Cleveland Clinic, Shaker Heights, OH

Meeting: ACR Convergence 2025

Keywords: ANCA associated vasculitis, Granulomatosis with Polyangiitis (GPA), Systemic lupus erythematosus (SLE), Vasculitis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, October 26, 2025

Title: (0711–0730) Vasculitis – ANCA-Associated Poster I

Session Type: Poster Session A

Session Time: 10:30AM-12:30PM

Background/Purpose: ANCA associated vasculitis (AAV) is a severe autoimmune disorder with substantial morbidity and mortality. Establishing the diagnosis might be challenging due to the existence of noteworthy mimickers, most notably infective endocarditis (IE) and drug-induced AAV. We aimed to identify differences in initial labs, serologies, clinical manifestations, and histopathology findings with the goal recognizing diagnostic clues that can raise suspicion for a secondary process.

Methods: A retrospective chart review was conducted on patients with glomerulonephritis (GN) secondary to IE, drug-induced AAV and primary AAV, from January 1, 2008, to January 1, 2024. Patients were filtered using SNOMED clinical terms of vasculitis and GN and any positive ANCA test. GN diagnosis was established either histologically or clinically by elevated creatinine and new onset hematuria with active urinary sediment. IE diagnosis was established by modified Duke Criteria or positive PCR on removed valve. Primary and drug induced AAV diagnosis were established by vasculitis specialist. Blood counts, and serologies were collected prior to any treatment including glucocorticoids. Statistical analysis included the use of Kruskal-Wallis test for continuous variables and Chi-square test for categorical variables.

Results: Baseline characteristics are outlined in Table 1. There were 42 patients with IE related GN, 35 with drug-induced AAV, and 50 with primary AAV. Median age at diagnosis was 58.4, 70.7, and 59.1 years, respectively. Bartonella was the most common microorganism (52.4%) in the IE-related GN group, and almost all drug-induced AAV cases (97%) were linked to hydralazine.Baseline labs and serologies are detailed in Table 2. Initial blood counts showed that IE-related GN and drug-induced AAV patients commonly presented with leukopenia (42.8% and 48.5%, respectively) and thrombocytopenia (90.4% and 37.1%, respectively) and seldomly presented with thrombocytosis (0% and 2.8%, respectively). Primary AAV patients frequently presented with leukocytosis (80%) and thrombocytosis (68%), and rarely with leukopenia (2%) and thrombocytopenia (2%). Median initial leukocyte, neutrophil, lymphocyte, and platelet counts were higher in primary AAV compared to other groups (p< 0.001). Hypocomplementemia was found in 76.2% of IE-related GN and 80% of drug-induced AAV cases, compared to 22% in primary AAV (p< 0.001). Majority of patients underwent renal biopsy (Table 3). C3 was the most common immunofluorescence staining in IE-related GN and drug-induced AAV. Dialysis cessation at 6 months occurred in 75% of primary AAV patients, whereas 30.7% of IE related GN patients, and 18.7% of drug-induced AAV patients (p< 0.001). Six-month mortality was significantly higher in IE related GN and drug induced AAV compared to primary AAV (p< 0.001).

Conclusion: The presence of cytopenia including leukopenia and thrombocytopenia, along with low complement levels upon presentation of IE related GN and drug-induced AAV can help clinicians to discern from primary AAV. Early recognition of these mimickers is critical, as they are associated with lower rates of renal recovery and higher six-month mortality.

Supporting image 1Table 1. Summary of study population characteristics and clinical presentation.

Supporting image 2Table 2. Laboratory values and serologies..

Supporting image 3Table 3. Renal biopsy findings and outcomes.


Disclosures: A. Vural: None; C. Zhang: None; Y. Kinanah: None; C. Calabrese: Eli Lilly, 2, Invivyd, 2, 6, sanofi, 2, 6; A. Brown: AbbVie/Abbott, 2, Amgen, 2, Sanofi, 2.

To cite this abstract in AMA style:

Vural A, Zhang C, Kinanah Y, Calabrese C, Brown A. Differentiating Primary Anti-Neutrophil Cytoplasmic Antibody (ANCA) Associated Vasculitis from Secondary Forms [abstract]. Arthritis Rheumatol. 2025; 77 (suppl 9). https://acrabstracts.org/abstract/differentiating-primary-anti-neutrophil-cytoplasmic-antibody-anca-associated-vasculitis-from-secondary-forms-2/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2025

ACR Meeting Abstracts - https://acrabstracts.org/abstract/differentiating-primary-anti-neutrophil-cytoplasmic-antibody-anca-associated-vasculitis-from-secondary-forms-2/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology